Iptacopan (FABHALTA®) is an oral complement Factor B inhibitor, which was approved on 5 December 2023 in the United States for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults. This evidence concerns the gene CFB and paroxysmal nocturnal hemoglobinuria.